Early, real-world experience with direct oral anticoagulants in the treatment of intermediate-high risk acute pulmonary embolism

Introduction: Intermediate-high risk pulmonary embolism (IHR-PE) has a poor prognosis, but is under-represented in trials of direct oral anticoagulants (DOACs) in venous thromboembolic disease (VTE). We aimed to assess whether the administration of DOACs was equivalent to the conventional (CONV) tre...

ver descrição completa

Detalhes bibliográficos
Autor principal: Santos, Sónia Martins (author)
Outros Autores: Cunha, Susana (author), Baptista, Rui (author), Monteiro, Sílvia (author), Monteiro, Pedro (author), Gonçalves, Francisco (author), Pêgo, Mariano (author)
Formato: article
Idioma:eng
Publicado em: 2017
Assuntos:
Anticoagulants
Venous thromboembolism
Real world
Pulmonary embolism
Intermediate-high risk
Warfarin
CHAVEAnticoagulantes
Tromboembolismovenoso
Mundo real
Embolia pulmonar
Risco intermédio aelevado
VarfarinaExperiência
Administration, Oral
Adult
Aged
Aged, 80 and over
Cohort Studies
Female
Humans
Male
Middle Aged
Pulmonary Embolism
Retrospective Studies
Risk Assessment
Young Adult
Texto completo:http://hdl.handle.net/10316/102117
País:Portugal
Oai:oai:estudogeral.sib.uc.pt:10316/102117

Texto Completo

http://hdl.handle.net/10316/102117

Registos relacionados